Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.35 |
| ▸ | RAB9A | P51151 | 5/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | TACR1 | P25103 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19240328 | 0.82 | HPGD (0.33) | NPC1LMNAL3MBTL1ALDH1A1 | |
| SCHEMBL19240330 | 0.82 | ALDH1A1 (0.42) | NPC1RAB9AMAPTALDH1A1IDO1 | |
| SCHEMBL19240332 | 0.82 | CYP4F2 (0.40) | MAPTESR1ESR2ALDH1A1CYP1A2 | |
| SCHEMBL19240327 | 0.82 | IDO1 (0.40) | NPC1MAPTALDH1A1IDO1CYP3A4 | |
| SCHEMBL19240334 | 0.81 | CA2 (0.41) | NPC1LMNAMAPTALDH1A1HTT | |
| SCHEMBL25860160 | 0.80 | SKP2 (0.34) | NPC1RAB9ALMNAMAPTL3MBTL1 | |
| SCHEMBL19240331 | 0.80 | CCR5 (0.31) | LMNA | |
| SCHEMBL19240325 | 0.80 | IDO1 (0.42) | IDO1 | |
| SCHEMBL648537 | 0.79 | AGXT (0.39) | ESR1ESR2IDO1 | |
| SCHEMBL7060861 | 0.78 | TSHR (0.40) | NPC1RAB9ALMNAMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | ONECUREGEN CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-8119653-B2 | Belactosin derivatives as therapeutic agents/biological probes and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | PSMB1, PSMB10, PBK | NPC1 4256/4885RAB9A 2986/4885LMNA 389/4885 |
| US-20230219894-A1 | DISUBSTITUTED ADAMANTYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION FOR SUPPRESSING CANCER GROWTH COMPRISING SAME AS ACTIVE INGREDIENT | AK2, CS, GOT2 | NPC1 1926/4885RAB9A 1523/4885LMNA 3870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.